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Allergic rhinitis in South African children:
There is something new in the air.
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Definition and prevalence
In 2001, a committee of prominent
allergists published a revised
nomenclature for allergic diseases,
including a definition of rhinitis (both
allergic rhinitis and rhinitis due to other
causes), which has both intermittent
and persistent expressions.1 This
document also classified allergy into
both IgE-mediated and non-IgE-
mediated allergy and defined it as ‘a
hypersensitivity reaction initiated by
immunological mechanisms’. This
document provided allergists with a
standardised nomenclature for allergy
and, within that, for allergic rhinitis. To
extend these definitions further, it can
be said that rhinitis is a pathological
term meaning ‘inflammation of the
lining of the nose’.2 Importantly, this is
a clinical diagnosis, relying on
characteristic clinical features,
including rhinorrhoea, itch and
sneezing (runners or sneezers), and
nasal congestion (blockers). This
particular classification was introduced
in the mid-1990s by the International
Rhinitis Working Group.2 It is also worth
emphasising that nasal congestion is
a prominent feature of perennial or
persistent allergic rhinitis, and is
responsible for significant clinical
manifestations, complications and
costs of the disease.
The expression of allergic rhinitis
in South Africa is mainly that of a
persistent disease, especially on the
Highveld of the country. The reason
for this is that seasonal allergens, in
the form of grass pollens, are present
for significant periods of time in the
atmosphere of this area.3,4 The ISAAC
(International Study of Asthma and
Allergy in Children) study was
published recently.5 This study
measured the prevalence of allergic
diseases, including allergic rhinitis, in
many countries around the world. In
South Africa, the prevalence of this
condition was 16% - 17% (of 13- to
14-year-old children), making it the
most common chronic condition in
children.
Allergic rhinitis, like other allergic
conditions, is on the increase around
the world. A number of reasons have
been postulated for this, and a
commonly cited cause is atmospheric
pollution. However, the most likely
explanation for the rising prevalence
is postulated in the form of the ‘hygiene
hypothesis’.6 This hypothesis states
that, as a result of a reduction in natural
infections in young children due to the
improvement of public health and
hygiene, the earlier use of antibiotics,
smaller family sizes and urbanised
living, the infectious trigger of the
immune system to produce TH1
lymphocytes is absent and the immune
system swings into a TH2 lymphocyte-
dominated system, which produces
the cytokines characteristic of allergic
diseases.
Diagnosis
Allergic rhinitis is largely a clinical
diagnosis. However, a high index of
suspicion needs to be retained, as
many patients and parents do not
complain of the direct symptoms of
this disease. More important are the
indirect features as a result of ongoing
nasal congestion, a hangdog or tired
facial expression, characteristic mouth
breathing, allergic shiners or dark rings
beneath the eyes, nasal crease and
a watery nasal discharge (see Figure
1). Allergy diagnostic testing usually
requires no more than skin-prick
testing. Skin-prick testing to common
aero-allergens, such as grass pollen,
tree pollen, house dust mite, cat and
dog, is usually sufficient, and extensive
skin-prick testing is generally not
required. Specialised laboratory testing
is seldom required if a clinical
diagnosis followed by skin-prick testing
is employed. Allergy testing in the form
of laboratory testing needs to be
undertaken in a cost-effective way and
it is seldom that extensive RAST testing
is required to make a diagnosis of
allergic rhinitis.
Introduction
Upper respiratory tract symptoms and problems are both common and troublesome in infants and children. Young
children get a number of viral upper respiratory tract infections per year, although the symptoms are frequently allergic
in origin. This article will address some of the new, as well as the often forgotten, issues in the understanding of allergic
rhinitis, especially in children and infants, and particularly in South Africa, where unique situations exist with regard to
this disease.              (SA Fam Pract 2005;47(6): 28-31
Figure 1: The Allergic Facies
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Complications
Very significant in allergic rhinitis are
the complications of the disease,
especially the complications of
p e r s i s t e n t  a l l e r g i c  r h i n i t i s .
Complications often relate to other
areas of the respiratory tract, including
the middle ear space, producing an
otitis media with effusion, and the sinus
cavities, producing both chronic
sinusitis and episodic infective acute
sinusitis. The long-face syndrome, with
dental malocclusions, and the
associated impaired quality of life are
very real and significant complications
of this disease.7
Probably the most important
complication of allergic rhinitis is
asthma. Up to 40% of asthma sufferers
have allergic rhinitis as a cause of
associated nasal symptoms (although
nasal symptoms occur in the majority).8
Asthma therefore has a very real
association with allergic rhinitis. There
have been a number of proposed
interactive theories for the association
between allergic rhinitis and asthma.
Aspiration of inflammatory secretions
from the upper airway down into the
chest is a theory that was proposed
in the eloquent work done by Phillip
Bardin in the Western Cape.9 The
nasobronchial reflex was also
postulated for many years to be the
link between the upper and lower
airway, but no evidence for this has
been found.10 Mouth breathing is
clearly present in individuals with a
persistent blocked nose and this may
result in the inspiration of poorly
humidified air and the inhalation of
greater quantities of allergens.
However, the most likely explanation
for the connection between upper and
lower airway disease relates to the
fact that these are expressions of a
systemically mediated condition.11
We have realised of late that a very
real complication of allergic rhinitis is
an impaired quality of life, so much so
that the quality of life of an individual
with allergic rhinitis is often as severely
impacted upon as having severe
asthma.12 This is very important at a
paediatric level. School performance
is impacted upon by poor sleep.13 It
is obvious that if allergic rhinitis and
asthma both impact on quality of life,
having both diseases, which occurs
in a large number of patients, is going
to impact that much more on the
quality of life of the individual.14
Treatment
In 1996, the South African Allergic
Rhinitis Working Group published a
document dealing with the clinical
expression, complications and
management of this disease.2 Topical
nasal corticosteroids form the mainstay
of the treatment of persistent allergic
rhinitis, especially the more moderate
and severe forms of this disease.
Topical nasal corticosteroids are safe
to use in the long term, even in young
children.
There is a significant place in the
management of allergic rhinitis for the
use of oral antihistamines, especially
newer-generation antihistamines,
which are non-sedating and long
acting. The recently published Gloria
Guidelines state the exact role for
antihistamines in both persistent and
intermittent disease (see Figure 2).15
The South African Allergic Rhinitis
Working Group document states that
the use of antihistamines in the
treatment of allergic rhinitis, whether
short term or long term, needs to focus
on the second and new generation
oral antihistamines that do not carry
the risk of sedation (which simply
exaggerates the impact on quality of
life) or tachyphylaxis.
Desloratadine, levocetirizine and
fexofenadine are more then just
antihistamines. They carry anti-allergic
and anti-inflammatory properties,
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Figure 2: The GLORIA Guidelines for treatment of allergic rhinitis
which translate into significant
advances in the therapeut ic
classification of the antihistamines.
The advantages of these agents are
many, such as their oral activity, their
non-sedating effect, their greater
potency and their favourable safety
profile. They are rapidly acting oral
antihistamines with an extended half-
life.16 The most important advantage
of these preparations, however, is
probably their ability to treat nasal
congestion or stuffiness.17
The Allergic Rhinitis Working Group
deals with the management of acute
symptoms. It should be stressed that
acute symptoms may imply the flare-
up of background disease that was
previously well controlled or, and
probably more importantly, the newly
diagnosed patient who has had
longstanding uncontrolled symptoms.
Acute therapy really means the
application of a topical or oral
decongestant and a newer generation
antihistamine for control. It is worth
noting that not all nasal decongestants
are equal. Imidazole-containing drugs
are preferable because of their
favourable safety profile. It should also
be remembered that the phenylephrine
group is banned for use by people
involved in competit ive sport.
Unfortunately, no therapy is registered
for chronic use in infants in whom
troublesome symptoms of allergic
rhinitis may be present. In this case,
it could be useful to consider saline
solutions.
A systemical ly-act ive ant i -
allergenic and anti-inflammatory drug
would have some effect on the other
expression of inflammatory airway
disease, namely asthma, and the use
of inhaled B2-agonists for asthma is
s ign i f i can t l y  reduced  when
desloratadine is used.18 In addition,
total asthma symptom scores are
reduced in asthmatics who are using
desloratadine for the control of allergic
rhinitis.19
The management of allergic rhinitis
needs a step-wise approach, similar
to the management of asthma, and
the use of a management card is
proposed. One of the pages of the
management card deals with regular
medic ines ( inc luding topical
corticosteroids or antihistamine for
milder symptoms). The card also
contains a plan for occasional
symptoms and an action plan for
dealing with persistent uncontrolled
symptoms. Doctors should be
encouraged to give this card to
patients (see Figure 3).
Conclusion
Allergic rhinitis is common in South
African children. The diagnosis rests
on a classic clinical picture and a
simple, cost-effective test to prove
allergy. Symptoms in South African
patients are usually persistent and
give rise to important complications,
as well as high costs. The treatment
of chronic disease differs from that of
acute and newly diagnosed disease
and it is worth remembering that newly
diagnosed disease often requires an
intervention step before regular
therapy is prescribed. The treatment
of persistent allergic rhinitis may
require a new-generation antihistamine
for the more mild forms of the disease,
and certainly as an add-on therapy
for minor exacerbations. Allergic
rhinitis, finally, is a cause of significant
sequelae, which are important in their
own right and also an important cost
driver for the health economy of our
country.
See CPD Questionnaire, page ??
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Use medication as per
Treatment Plan
Figure 3: Management Card for Allergic Rhinitis
